Badri Rengarajan

Badri is a North America Regional Medical Affairs Director for Zepzelca/oncology at Jazz Pharmaceuticals. Badri served as study physician for the largest observational study in the MF variant of cutaneous T-cell lymphoma (an ultra-rare disease), co-led the investigator-initiated study program for ASPIRE, and oversaw an interdisciplinary effort across medical affairs, field medical, and clinical operations. ​